Discontinued — last reported Q4 '24
Products & Services · Revenue
COVID-19 Antibodies — Revenue
Over 3 years (FY 2021 to FY 2024), COVID-19 Antibodies — Revenue shows a downward trend with a -100.0% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityVolatile
First reportedQ1 2019
Last reportedQ4 2024
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful deployment or continued demand for pandemic-related therapeutics, while a decrease reflects the natural decline of the product lifecycle as the pandemic transitions to an endemic state or as alternative treatments emerge.
Detailed definition
This metric represents the total net sales generated from the company's portfolio of therapeutic antibodies specifically...
Peer comparison
Comparable to pandemic-related product revenue streams reported by other large-cap pharmaceutical firms, which often exhibit significant volatility and rapid decline following the peak of a public health crisis.
Metric ID:
lly_segment_covid_19_antibodies_revenueHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $148.90M | $217.10M | $1.06B | $1.47B | $129.10M | $386.60M | $34.30M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +45.8% | +390.1% | +38.2% | -91.2% | +199.5% | -91.1% | -100.0% | — | — | — | — | — | — | — |
| YoY Change | — | — | — | — | -13.3% | +78.1% | -96.8% | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — |
Range$0.00 – $1.47B
CAGR-100.0%
Avg YoY Growth-61.7%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's covid-19 antibodies — revenue?
- Eli Lilly (LLY) reported covid-19 antibodies — revenue of $0.00 in Q4 2024.
- What is the long-term trend for Eli Lilly's covid-19 antibodies — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's covid-19 antibodies — revenue has grown at a -100.0% compound annual growth rate (CAGR), from $2.24B to $0.00.
- What does covid-19 antibodies — revenue mean?
- The total revenue earned from the sale of COVID-19 antibody treatments.